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Background: Osteoporosis is a chronic disease and adherence can fluctuate
over time. Therefore, longer observation is necessary to investigate the stability of
patients’ adherence. The study aim was to compare the overall adherence (OA)
to supplementation with the fixed combination of calcium and vitamin D (Ca/D) in
postmenopausal women at baseline and after 1 year, and to evaluate the fluctuation of
the OA in individual months. Furthermore, we studied whether adherence is influenced
by signing of informed consent and routine medical check-up.
Methods: This was a longitudinal, observational study. The data were obtained from the
Osteocenter of University Hospital in Hradec Kralove, Czech Republic. Adherence was
measured using electronic bottles type Medication Events Monitoring System (MEMS).
The study was carried out in two 3-month periods; the baseline in 2013 (signing of
informed consent while medical check-up) and the follow-up (medical check-up) in 2014.
The adherence and adherence-related outcomes were studied in patients who had
initiated osteoporosis treatment and were persistent.
Results: 21 (49%) out of 43 patients who avoided drug dispenser and were persistent
both at baseline and at follow-up, completed the study and were included. Median
age was 76. Evaluating the whole 3-month periods, the OA did not differ significantly
at baseline and at follow-up, the OA was 71 and 68%, respectively. However, the
adherence in month 1 at baseline was significantly higher than the adherence in month 2
at baseline (p < 0.001) and also than the adherence in month 1 at follow-up (p = 0.010).
Analysing the study period without month 1, a stable adherence was observed in 48%
of patients. About 33% of doses were omitted at baseline and 34% at follow-up. As
many as 71% of the patients took drug holidays at baseline, and 76% at follow-up.
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Conclusion: The OA was insufficient, around 70% both at baseline and at follow-up.
One half of the patients showed a stable adherence. The patterns of non-adherence were
very similar at follow-up. Signing of the informed consent seems to act as bias more than
regular medical check-up.
Keywords: medication adherence, patient adherence, longitudinal studies, medication event monitoring system
(MEMS), drug holidays, osteoporosis, calcium supplementation, electronic monitoring
INTRODUCTION
Osteoporosis is defined as a chronic systemic disease of skeleton
characterized by low bone mineral density which resulted in an
increased risk of fractures. Changes in microarchitecture of bone
tissue can also significantly contribute to bone fragility (Kanis
et al., 2013).
A lot of medications for the treatment of osteoporosis
have been proven to reduce fracture risk in postmenopausal
women. Antiresorptive drugs, such as bisphosphonates, which
prevent accelerated decrease of bone mass associated with age,
are widely recommended and used (Kanis et al., 2013). All
treatment regimens should include adequate intakes of calcium
and vitamin D (Ca/D). Daily doses of 1000mg of calcium and
800 international units (IU) of vitamin D or even higher can
be generally recommended (Kanis et al., 2013). According to
the study of Tang et al. (2007), supplementation with Ca/D was
associated with a 24% reduction in the fracture risk in patients
sufficiently adherent to the supplements.
Non-adherence to medical therapy is a widespread public
health problem. It is estimated that only a half of the patients
comply with a long-term therapy (Kanis et al., 2013). Especially
in chronic asymptomatic diseases, overcoming of non-adherence
presents a particular challenge (Kanis et al., 2013). This fact is
well-documented by the results of recent studies concerning the
treatment of osteoporosis, in which the adherence to long-term
Ca/D supplementation ranges between 30 and 75% (Sanfelix-
Genovés et al., 2009; Castelo-Branco et al., 2010; Díez et al., 2012;
Touskova et al., 2015).
The work of Voils et al. (2011) which deals with the
methodology for measuring adherence concluded that
longitudinal evidence is needed to illuminate whether episodic
or chronic non-adherence is more common. As it is possible
that patients who are non-adherent in cross-sectional studies
will become adherent year after year and vice versa (Ngui et al.,
2013), and that adherence may vary over the time, repeated
measures are necessary to identify non-adherent patients more
adequately (Tesoriero et al., 2003).
In the field of adherence evaluation, one of themost important
problems is that traditional methods (pill counts, questionnaires,
patients’ diaries) have repeatedly been shown to overestimate
adherence (Shi et al., 2010a,b). Further, adherence could be
unwittingly overestimated whenmeasured retrospectively (Zeller
et al., 2008a).
A reliable evaluation of poor adherence, including early
discontinuation, can be performed over a long term follow-
up from the timing of refilled prescriptions in population
databases. However, refills do not capture medication-taking
habits, including the exact time when the patient discontinued
taking the medication. Thus, the most reliable method for
measuring the adherence is the use of Medication Event
Monitoring System (MEMS; Osterberg and Blasche, 2005).
Although this objective method is also connected with some
questionable aspects, these could be mostly overcome by means
of appropriate design of the study.
There could be an influence of signing a written consent as
patients who provide it might be more motivated and adherent
than those who refused to participate (Cheng et al., 2004). Some
works show a mild improvement of adherence in connection
with a medical check-up (Feldman et al., 2007; Gillespie et al.,
2014). Nevertheless, it is necessary to further investigate these
hypotheses.
Based on abovementioned facts our study aimed (Kanis et al.,
2013) to compare the adherence to Ca/D at baseline and after
12 months of the treatment in postmenopausal women with
osteoporosis (Tang et al., 2007). To evaluate the fluctuation of the
adherence in individual months and (Touskova et al., 2015) to
find out if the adherence is influenced by the entry to the study
(written consent) and medical check-up.
METHODS
Study Design, Setting, and Participants
A longitudinal, observational study was performed in secondary
care female patients at the risk of osteoporosis-related fracture.
The study was carried out in two periods lasting 3 months each;
the baseline from June to September 2013 and the follow-up from
June to October 2014. Study participants were recruited from the
outpatient Osteocenter in University Hospital in Hradec Kralove,
Czech Republic which specializes in providing care to patients
with osteoporosis.
Detailed methodology including the inclusion and exclusion
criteria are described elsewhere (Touskova et al., 2015). Briefly
summarized, the adherence to a fixed combination of calcium
and vitamin D (Ca/D), preparation Caltrate 600mg/400 IUD3 R©
(tablets) was evaluated. One tablet once a day was prescribed
to all participants. Postmenopausal women older than 55 years
with the diagnosis of osteoporosis and concurrent treatment with
oral ibandronate were recruited. Exclusion criteria were non-
initiation and non-persistence with the Ca/D treatment, failure to
adhere to the study protocol and the use of a drug dispenser. Each
patient got aMEMS bottle containing 90 tablets of Ca/D (amount
for 3 months) in both rounds. The monitoring of the adherence
was performed in the same way at baseline and at follow-up.
Electronic monitoring using MEMS is an objective indirect
method of measuring adherence, indicating when a medication
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FIGURE 1 | Study design.
has been used. Each opening of the bottle is detected and obtained
records are analyzed. Although a patient may just open the
bottle without use of the medication or may use other than the
prescribed dose, distortion of results by these limitations can be
estimated (e.g., multiple openings in a short time can indicate
experimenting with the MEMS-bottle, openings once a week can
indicate use of weekly drug dispenser).
The study protocol has been approved by Ethics Committee,
University Hospital Hradec Kralove. Each patient agreed with
her inclusion in the study by signing informed consent during
a regular medical check-up in the osteocenter at baseline. After
3 months of monitoring, the patient gave the MEMS bottle back
(without medical check-up). If the patient had agreed with her
continuation in the study, she would be provided with theMEMS
bottle again during a regular medical check-up 12 (±1) months
after the beginning of the baseline without signing informed
consent again (at the moment). The MEMS bottle was returned
to the osteocenter after 3 months of the follow-up monitoring
(without medical check-up), see Figure 1.
Outcome Measures
In this article, the term adherence is used. It is a synonym
for compliance (closeness to treatment recommendation, often
simplified as the number of doses indeed taken related to the
number of prescribed doses), however the term compliance
embeds a more paternalistic doctor/patient relationship. The
term persistence expresses duration of the treatment, i.e., how
long the medication is taken (Dezii, 2001; Vrijens et al., 2012;
Kanis et al., 2013). We studied adherence-related outcomes in
patients who had initiated osteoporosis treatment and were
persistent both at baseline and at follow-up i.e., implementation
phase (Vrijens et al., 2012). Adherence ≥80% was considered as
good, adherence <80% as poor (Cramer et al., 2007).
Definitions:
• Overall adherence (OA, primary outcomemeasure): ratio of
the number of container openings to the number of prescribed
doses. The OA can exceed 100%.
• Difference in overall adherence: The overall adherence at
follow-up period minus the overall adherence at baseline
period. The change of 20% or more was considered as a
marked increase or marked decrease.
• Stable adherence: OA in each study month did not exceed
10% difference from the mean OA of the whole study period.
• Single or sequentially missed multiple doses (omissions of
dose):We focused on the omissions of a dose on a single day,
two consecutive days and drug holidays, defined as a sequence
of at least three consecutive days without taking the drug. We
defined the omission of a dose on a single day (24 h) as Ca/D-
free interval from 3 a.m. to 3 a.m. (the next day). A similar rule
was used to define the omission of more than 1 day (Vrijens
et al., 2012).
• Non-persistence: gap in the use of Ca/D to be 30 days or more
(Cramer et al., 2007; Kothawala et al., 2007).
Data Processing and Statistical Analysis
Most variables did not follow a normal distribution and therefore
non-parametric statistics were applied. Changes in adherence-
related outcomes in two time periods, i.e., follow-up vs. baseline,
pairs of individual months, were tested by using Related-samples
Wilcoxon Signed Rank test. Statistical analyses were calculated
using PASW software (version 18.0). P < 0.05 was considered
statistically significant.
RESULTS
Of 43 (39) patients who were addressed (enrolled andmonitored)
at baseline, as many as 21 (49%) completed both periods and
met the inclusion criteria. These 21 patients did not use drug
dispenser and were persistent both at baseline and at follow-
up and therefore were included in the present analysis. The
flow of patients through the study and the reasons for exclusion
from the analysis are shown in Figure 2. Median age (minimum-
maximum) of the included patients was 76 (60–83) years. The
number of patients excluded by reason of non-persistence was
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FIGURE 2 | Study organization. Patients who met the exclusion criteria at baseline and/or at follow-up were not included in the analysis. The same patients who
were enrolled and monitored at baseline (even those finally excluded) were addressed at follow-up. Therefore, patients who were excluded at baseline, were enrolled
at follow-up. Although they did not meet the exclusion criteria at follow-up, they cannot be (due to non- persistence and/or use of drug dispenser at baseline) included
in the analysis.
6/4 (baseline/follow-up). From this count only one patient was
non-persistent in both rounds. A few patients (4/7) refused to
participate in the study. In the follow-up they stated reasons such
as a planned holiday or inconvenience with MEMS bottle. From
seven patients who refused to cooperate in the follow-up, only
one was non-persistent at baseline. As many as 4/6 patients were
excluded by reason of using a drug dispenser (4 patients from the
baseline continued with this habit and 2 others started with it).
None of these patients was non-persistent.
No multiple openings of the MEMS container within a period
of ≤15min were observed.
Difference in Overall Adherence
The overall adherence did not differ significantly at baseline
period and the follow-up, the overall adherence was 71 and 68%,
respectively. The adherence of 1 patient (5%) increased markedly
and of 3 patients (14%) decreased markedly, see Figure 3. A good
adherence (≥80%) was observed in 62% of the patients at baseline
and 57% at follow-up. The overall adherence at follow-up was
78% in patients showing good adherence at baseline, compared
to 51% in patients with a poor adherence at baseline.
Stability in Adherence by Study Month
Changes in the overall adherence by a study month are shown in
Figure 4. The adherence in month 1 at baseline was significantly
higher than the adherence in month 2 (p < 0.001) and also
significantly higher than the adherence in month 1 at follow-up
(p = 0.010). On the contrary to month 2 vs. month 1 at baseline,
the differences in the adherence when evaluating the pairs of
consecutive months were not significant.
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FIGURE 3 | Difference in mean overall adherence at follow-up and
baseline.
As many as 33% of patients maintained a stable adherence.
When analyzed the study period without month 1, i.e., from
month 2 at baseline to month 3 at follow-up, a stable adherence
was observed in 48% of patients.
Non-adherence Patterns
As many as 33% of doses were omitted at baseline and 34% at
follow-up. The categorizations of these omissions at baseline and
follow-up are showed in Figure 5.
As many as 71% of the patients took drug holidays at baseline
and 76% at follow-up. Patients without drug holidays were fully
compliant, the overall adherence was 102% at baseline and 98%
at follow-up.
Variables describing patterns of non-adherence such as single-
day omissions, 2-day omissions, drug holidays, and the longest
drug holidays did not differ significantly at baseline and at follow-
up. To demonstrate similar patterns in adherence at baseline and
follow-up in most patients we present two cases (Figures 6, 7).
DISCUSSION
The presented longitudinal prospective study was conducted to
investigate the adherence over the period of more than 1 year.
Because adherence can fluctuate over time, we observed patients
non-persistent at baseline also during the follow-up, although
it is unusual (especially in database studies; Kothawala et al.,
2007; Lekkerkerker et al., 2007). The majority of patients non-
persistent at baseline was persistent at follow-up, which generates
the signal that in many cases patients restart successfully with the
treatment. Non-persistence, up to a point, can be thus considered
as extremely long drug holidays.
The design of the study has been approached unusually in
comparison with other studies (Cheng et al., 2004; Parker et al.,
2007)—the monitoring was not held during the whole year but
with a nine-month pause. The reason for this was our attempt to
compare the influence of the entry to the study (informed consent
signing) and the medical check-up (the first and the twelfth
month of the study) on adherence of patients. Some authors state
a mild improvement of adherence in connection with themedical
check-up (Feldman et al., 2007; Gillespie et al., 2014), but this
behavior was observed only partly in our study. Patients were
significantly more compliant the first month after the medical
check-up compared to following 2 months at baseline. On the
other hand, adherence after the medical check-up did not change
in comparison with next 2 months at follow-up. Thus, the
significantly higher adherence in the first month after study entry
is more likely to be linked with the signing of informed consent
than the medical check-up. It seems that even though patients
have not known about electronic monitoring of adherence, the
very fact of signing the informed consent could play the role
of bias. Based on these findings we suggest that further studies,
similar to ours, should analyse adherence after the initial period,
as it is probably influenced by bias of signing the informed
consent.
The overall adherence (OA) was insufficient, around 70% both
at baseline and follow-up. It changed markedly only in one fifth
of the patients at follow-up. If we do not consider adherence in
the first month, which suggests the influence of social desirability
bias, we observed a stable adherence in one half of the patients
during particular months (max ± 10% of the mean counted for
all 5 months); one half of the patients showed higher fluctuation.
As an adequate intake of calcium and vitamin D is essential for
the successful treatment of osteoporosis and our results confirm
an insufficient adherence to the supplementation of Ca/D, we
emphasize the role of diligent patient education in the field of an
appropriate diet, rich in these key nutrients, in clinical practice.
We observed good adherence (≥80%) in fewer patients
(around 60%) than Cheng et al. (around 80%), who studied
adherence to statin therapy in the cohort of Chinese patients. In
this MEMS-based study, all patients had a history of coronary
heart disease (CHD) events or CHD-equivalent risk (Cheng
et al., 2004). One reason can be that patients do not perceive
the supplementation therapy with Ca/D as much important
compared to statin therapy in secondary prevention. The
supplementation can be viewed as if it “only” accompanied
specific antiresorptive treatment (ibandronate) which is believed
to be the main medication that reduces fracture risk. In the
study of Cheng et al. adherence slightly decreased during the
first months and tended to normalize from the third month
onwards (Cheng et al., 2004). This initial decrease in adherence
could be explained by the inclusion criteria i.e., patients who
had been initiated on statin monotherapy for <12 months.
Their cohort was therefore probably closer to the beginning
of treatment than our treatment-experienced group and the
initial decline in adherence behavior toward statins can be more
apparent.
In the MEMS-based study of adherence (Parker et al., 2007)
including 145 participants within 2 months of initiating warfarin
therapy, adherence was around 80% and changed over time.
Authors observed initial worsening over the first 6 months
of monitoring, which was followed by improvement beyond
6 months. Similarly, compared to our findings, high level of
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FIGURE 4 | Levels of overall adherence (OA) at baseline and follow-up by month (minimum, 25th percentile, median, 75th percentile, and maximum).
FIGURE 5 | Omitted doses within single-day omission, 2-day omission, and drug holidays (%); all omitted doses represent 100%. Drug holidays, a
sequence of at least 3 consecutive days without taking the drug.
adherence and initial decline could be explained by higher
perceived necessity of treatment and inclusion of treatment-naive
patients only. The improvement in adherence to warfarin therapy
was explained as a result of loss of anticoagulation and potential
benefit from interventions.
Within a psychiatric field, as many as 81% of patients with
schizophrenia adherent in the first year were adherent in the
second year. Adherence status was relatively stable over time, as
most patients (77%) maintained the same adherence status in the
second year compared to the first year. However, in this large
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FIGURE 6 | Case report 1: Overall adherence of the patient at baseline and follow-up is very high, adherence over time is stable at baseline and follow-up. The patient
used her medication regularly in the evening as prescribed by her doctor. The same trend of use was found in most participants both in timing and dosage.
study, a stable adherence was defined in a less stringent way than
in our study, therefore the stability of the adherence in our cohort
was lower.
The assessment of adherence over time is particularly studied
in HIV-positive patients. However, these patients usually come
from different socioeconomic background and probably perceive
their condition as serious and life-threatening. Not surprisingly,
adherence mostly declines with time. A review including studies
with predominantly treatment-experienced cohorts cared for in
the United States found out that the decline is not consistent
across studies (Wilson et al., 2013). The study with HIV-infected
adults (Shuter et al., 2012) evaluated adherence to antiretroviral
therapy with the use of MEMS in two observational periods
in the interval of 3 years; the mean adherence rates were 74
and 69%. In another study, adherence measured by using self-
reported interviews was 81% in patients, who were adherent at
baseline, compared to 58% in those non-adherent at baseline
(Tesoriero et al., 2003). Even though these findings seem similar
to ours, comparisons are not appropriate since adherence inHIV-
infected patients is a specific problem different from chronic
civilizational conditions (such as osteoporosis) mostly perceived
as non-life threatening.
The patterns of non-adherence within a 3-month period were
very similar after 1 year. During the follow-up the percentage of
patients with drug holidays was slightly higher in comparison
with the baseline at the expense of single day omission, but the
differences were not significant. Over 70% of patients in our
study took drug holidays in both rounds. The finding the patients
who had used the pill box at baseline also used it at follow-
up is in accordance with the basically unchanging “adherence
patterns.” The pattern is probably more important and helpful
for the patients than physician’s instruction associated with the
study.
Limitations and Strengths
The main limitation of our study is a relatively small sample
size. Pilot and qualitative studies generate signals and hypotheses;
no generalization is possible. We wanted to approach the
clinical practice as close as possible—to maximally minimize bias
regardless a lower number of participants.
The adherence rate observed might be biased by the fact
that the patients who gave consent to participate in the study
might have been more motivated to adhere to therapy than those
patients who refused to participate. The fact that the patients were
recruited directly from the Osteocenter could positively affect
the final behavior of the sample willing to participate but it is a
general problem of such studies.
The strength of our study is that we describe the loss of
patients at both baseline and follow-up in detail, and reasons for
exclusion, which is important since it shows adherence-related
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FIGURE 7 | Case report 2: Just like the previous patient, she used her medication mostly in the evenings. Although her overall adherence is lower, it is still stable with
the difference in the overall adherence being insignificant. The trend of omitted doses resulting in drug holidays is similar as well; we can see dose omissions on single
days, two consecutive days, and eventually drug holidays, whose frequency is slightly increased at follow-up.
behavior as a whole. Some studies either do not mention the
loss of follow-up or simply note that those lost to follow-up
were excluded from analysis (Wilson et al., 2013). We observed
adherence in treatment-experienced patients and involved only
persistent patients, who are compliant with medical check-ups
and agreed with their inclusion in the study—they signed the
informed consent. With regard to these strict criteria only less
than one half of the patients addressed were involved in the
study. It is about more than 20% less than e.g., in the study
with patients treated with statins (persistent and non-persistent)
measuring adherence by means of MEMS (Cheng et al., 2004).
In statin study, which comprised 70% of patients the crucial
reasons for excluding patients were similar—11 patients refused
to participate and 15 transferred drugs to their pill-boxes (Cheng
et al., 2004). Contrary to our study, Cheng et al. had also minor
problems such as patients referred to clinics other than the study
clinics, insistence on using pill-box, loss of the MEMS bottle, and
closing the bottle cap properly.
Patients who know they are monitored improve their
adherence; this bias is usually referred as Hawthorne effect
(Parker et al., 2007; Zeller et al., 2008b; Maqutu et al., 2011;
McCambridge et al., 2014). That is why we informed patients
in a similar way as in the study of Cheng (Cheng et al.,
2004)—a patient agreed with her involvement in the study by
means of informed consent. A patient was informed about the
purpose of the study, but it was not specified, that the pill
bottle is electronic and intended to record adherence (if she
did not ask actively). Thus, patients probably did not have
suspicion of being monitored, because no patient asked about
the purpose of using the unusual bottle. Therefore, we suppose
“real-world-non-adherence patterns” were kept to a great
extent.
CONCLUSION
In conclusion, the adherence was insufficient (around 70%)
at baseline and at follow-up and did not change significantly
in individual months. The patterns of non-adherence were
similar after 1 year, and over two thirds of patients in our
study took drug holidays in both rounds. It seems that
signing the informed consent acts as bias more than a medical
check-up does, but it is necessary to further investigate this
phenomenon.
For clinical practice, the following can be summarized: In
MEMS-based studies, it seems appropriate to analyse adherence
without the initial data, which are probably influenced by
bias of signing the informed consent. Diligent and repeated
education of patients with osteoporosis regarding an appropriate
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diet is needed. The importance of sufficient intake of calcium
and vitamin D should be emphasized during each medical
check-up.
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